The sensitivity analysis excluding patients with baseline DPP4I or SGLT2I use showed a consistent association of GLP-1 RA use and significantly lower risk of MACCE (HR, 0.73; 95% CI, 0.57-0.95; P = .01) (eFigure in Supplement 1), all-cause mortality, new-onset HF, decompensated HF, AKI or progression to ESKD, and other CV events (eTable 2 in Supplement 1). This evidence concerns the gene GCG and acute kidney injury.